ISA to Present at the 4th Annual Virtual H.C. Wainwright HBV Conference on October 25th

24 Oct 2023

Oegstgeest, The Netherlands, 24 October 2023 – ISA is pleased to announce that it will be presenting during the 4th Annual H.C. Wainwright Virtual HBV Conference – October 25th. The presentation by Gerben Moolhuizen, CEO of ISA Pharmaceuticals, will highlight key characteristics and progress in the development of ISA104, a therapeutic vaccine aimed to aid in achieving  functional cure of patients suffering from chronic hepatitis B infection.

Presentation details:

4th Annual Virtual H.C. Wainwright HBV Conference

Date: 25 October 2023

Presentation title: Targeted Immune System Activation using SLPs in chronic HBV

Time: 5:00 – 5:30pm CET

ISA104 immunotherapy has been designed to create a strong and

Read more »

First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

31 Aug 2023

Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B infection

Oegstgeest, The Netherlands, 31 August 2023 – ISA is pleased to announce that the first patient has been dosed in the HEB-PEP study. This first-in-human (FIH) phase 1 study investigates the use of ISA104, a novel treatment aimed to establish functional cure in Chronic Hepatitis B patients. Dosing took place at the Liver Unit of the Erasmus Medical Center in Rotterdam, the sponsor of this dose escalation study.

The HEB-PEP study will investigate the safety, tolerability and efficacy of different doses of ISA104 in

Read more »